Literature DB >> 18766311

[Worsening in patients treated in acute stroke units--results of the Austrian Stroke Unit Registry].

Julia Ferrari1, Agathe Flamm-Horak, Agnes Lischka-Lindner, Michael Knoflach, Stefan Schnabl, Wilfried Lang.   

Abstract

Up to one-third of patients admitted to a hospital due to an ischemic stroke or a transient ischemic attack show clinical worsening of symptoms in the first hours to days after admission. We analyzed on the basis of a large patient group the frequency of minor or major worsening and the possible predictors for worsening. In the nationwide Austrian Stroke Unit Registry, 11616 patients with ischemic stroke or transient ischemic attack and a known NIHSS on admission and discharge from the stroke unit were recorded between March 2003 and February 2007. 363 (3.13%) of these patients showed a minor deterioration (NIHSS difference between admission and discharge 2 or 3 points) and 559 (4.81%) a major deterioration (NIHSS difference 4 or more points). In a logistic regression model, diabetes mellitus [OR (95%CI) 1.8 (1.3-2.4)], arterial hypertension [1.8 (1.2-2.8)], a cardiogen embolic event [1.6 (1.1-2.4)], and a large vessel disease [1.7 (1.2-2.6)] were independent predictors for a minor deterioration. Predictors for a major deterioration were a higher age [1.0 (1.0-1.1)], hypertension [1.4 (1.1-2.0)], diabetes mellitus [1.5 (1.2-1.9)], a higher NIHSS at admission [1.1 (1.0-1.1)], and a large vessel disease [1.8 (1.3-2.4)]. This underlines the importance of early diagnostic workup and risk evaluation in order to prevent also early deterioration by immediate initiation of dedicated therapeutic approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18766311     DOI: 10.1007/s10354-008-0565-4

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  10 in total

1.  Different predictors of neurological worsening in different causes of stroke.

Authors:  H Yamamoto; J Bogousslavsky; G van Melle
Journal:  Arch Neurol       Date:  1998-04

2.  Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I.

Authors:  A Dávalos; D Toni; F Iweins; E Lesaffre; S Bastianello; J Castillo
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

3.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials.

Authors:  T J DeGraba; J M Hallenbeck; K D Pettigrew; A J Dutka; B J Kelly
Journal:  Stroke       Date:  1999-06       Impact factor: 7.914

4.  Neurologic worsening during the acute phase of ischemic stroke.

Authors:  Christian Weimar; Thomas Mieck; Joachim Buchthal; Christiane E Ehrenfeld; Elisabeth Schmid; Hans-Christoph Diener
Journal:  Arch Neurol       Date:  2005-03

5.  Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire Community Stroke Project.

Authors:  H Tei; S Uchiyama; K Ohara; M Kobayashi; Y Uchiyama; M Fukuzawa
Journal:  Stroke       Date:  2000-09       Impact factor: 7.914

6.  Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK).

Authors:  Christopher S Gray; Anthony J Hildreth; Peter A Sandercock; Janice E O'Connell; Donna E Johnston; Niall E F Cartlidge; John M Bamford; Oliver F James; K George M M Alberti
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

Review 7.  Organised inpatient (stroke unit) care for stroke.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 8.  How do stroke units improve patient outcomes? A collaborative systematic review of the randomized trials. Stroke Unit Trialists Collaboration.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Lacunar stroke is the major cause of progressive motor deficits.

Authors:  Wolfgang Steinke; Stephan C Ley
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

Review 10.  Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies.

Authors:  J K Lovett; A J Coull; P M Rothwell
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.